Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England

Webster, H H and Nyberg, T and Sinnathamby, M A and Aziz, N Abdul and Ferguson, N and Seghezzo, G and Blomquist, P B and Bridgen, J and Chand, M and Groves, N and Myers, R and Hope, R and Ashano, E and Lopez-Bernal, J and De Angelis, D and Dabrera, G and Presanis, A M and Thelwall, S (2022) Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England. Nature Communications, 13 (1). ISSN 2041-1723

Full text not available from this repository.

Abstract

The Omicron variant of SARS-CoV-2 became the globally dominant variant in early 2022. A sub-lineage of the Omicron variant (BA.2) was identified in England in January 2022. Here, we investigated hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) compared to BA.1 (n = 984,337) in a large cohort study in England. We estimated the risk of hospital attendance, hospital admission or death using multivariable stratified proportional hazards regression models. After adjustment for confounders, BA.2 cases had lower or similar risks of death (HR = 0.80, 95% CI 0.71-0.90), hospital admission (HR = 0.88, 95% CI 0.83-0.94) and any hospital attendance (HR = 0.98, 95% CI 0.95-1.01). These findings that the risk of severe outcomes following infection with BA.2 SARS-CoV-2 was slightly lower or equivalent to the BA.1 sub-lineage can inform public health strategies in countries where BA.2 is spreading.

Item Type:
Journal Article
Journal or Publication Title:
Nature Communications
Additional Information:
© 2022. Crown.
Uncontrolled Keywords:
/dk/atira/pure/subjectarea/asjc/3100
Subjects:
ID Code:
177941
Deposited By:
Deposited On:
26 Oct 2022 07:20
Refereed?:
Yes
Published?:
Published
Last Modified:
22 Nov 2022 11:59